[{"orgOrder":0,"company":"KeifeRx","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series A Financing","leadProduct":"Nilotinib","moa":"ABL1","graph1":"Neurology","graph2":"Phase II","graph3":"KeifeRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"KeifeRx \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"KeifeRx \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals by KeifeRx

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Peptide-Based Therapeutics Summit
                          Not Confirmed
                          Peptide-Based Therapeutics Summit
                          Not Confirmed

                          Details : Proceeds from the financing will advance pipeline of optimized, low dose, orally delivered tyrosine kinase inhibitors including Nilotinib BE for the treatment of multiple neurodegenerative diseases.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          August 12, 2021

                          Lead Product(s) : Nilotinib

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : $6.0 million

                          Deal Type : Series A Financing

                          blank